Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN  Blood. 2025;146(11):1276–1285
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40198878

Asbestos Exposure and Leukemia Incidence: A Systematic Review and Meta-analysis  In Vivo. 2025;39(5):2739–2751
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40877187

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton’s tyrosine kinase inhibitors  Internal Medicine Journal. 2025;55(9):1556–1569
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40713941

Biologics for eosinophilic oesophagitis: a systematic review and meta-analysis  Annals of Medicine. 2025;57(1):2445192
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39707826

Co-occurrence of five chemotherapy induced nail findings  Journal of Hospital Medicine. 2025;20(10):1149–1150
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40745863

Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS  Clinical Lymphoma, Myeloma & Leukemia. 2025;25(10):746–758.e6
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40360369

Development of Adult T-Cell Leukemia/Lymphoma During Treatment with PD-L1 Inhibitor for Lung Cancer  Internal Medicine. 2025;64(18):2760–2763
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40058855

Disseminated Nocardiosis in Idiopathic CD4 Lymphocytopenia: A Rare Case and Literature Review  Internal Medicine. 2025;64(18):2797–2803
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40159158

Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase ½ (FANCOLEN-1) and long-term clinical trials  Lancet. 2025;404(10471):2584–2592
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39642902

Immunoglobulin A Nephropathy in a Kidney Transplant Recipient with Kabuki Syndrome  Internal Medicine. 2025;64(17):2619–2625
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40090720

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial  Haematologica. 2025;110(9):2024–2039
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40079105

Inpatient Rehabilitation Outcomes of Cancer Patients After Chimeric Antigen Receptor T-Cell Therapy  American Journal of Physical Medicine and Rehabilitation. 2025;104(9):821–825
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40396674

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial  Haematologica. 2025;110(9):2139–2150
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40109195

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia  New England Journal of Medicine. 2025;393(12):1177–1190
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40521799

Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia  New England Journal of Medicine. 2025;393(9):879–886
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40902162

Multiple Myeloma in a Patient with Birt-Hogg-Dubé Syndrome  Internal Medicine. 2025;64(18):2764–2768
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40090716

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments  Journal of Internal Medicine. 2025;298(4):297–318
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40778417

Prevalence of Heparin-Induced Thrombocytopenia in Hospitalized Patients With Antiphospholipid Syndrome or Lupus With Antiphospholipid Antibodies  American Journal of Medicine. 2025;138(9):1304–1307
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40228597

Rituximab as an Effective Treatment for New-onset Evans Syndrome and Systemic Lupus Erythematosus with Lupus Nephritis  Internal Medicine. 2025;64(17):2631–2636
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40090718

Role of a Bioelectrical Impedance Analysis in Predicting Anemia among Cardiovascular Disease Patients  Internal Medicine. 2025;64(17):2534–2540
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40090721

Self-reported Demographics of 154 Hypermobile Ehlers-Danlos Syndrome Patients  American Journal of Physical Medicine and Rehabilitation. 2025;104(10):927–932
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40300043

Systematic Literature Review of DOACs as Treatment for Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)  Annals of Pharmacotherapy. 2025;59(11):1015–1030
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40411430

Systematic review of cost-effectiveness modelling studies for haemophilia  Journal of Medical Economics. 2025;28(1):89–104
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39693522

Therapy-related Trilineage Mixed Phenotype Acute Leukemia Treated with Venetoclax and Azacitidine  Internal Medicine. 2025;64(17):2646–2651
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39924229

Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study  Internal Medicine. 2025;64(18):2692–2698
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40090722